Education
About Us
Working with TipRanks
Follow Us
Arvinas Holding Company (ARVN)
NASDAQ:ARVN
ARVN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.90 - $30.24
Previous CloseN/A
Volume216.17K
Average Volume (3M)1.78M
Market Cap
$575.90M
Enterprise Value$469.64M
Total Cash (Recent Filing)$954.30M
Total Debt (Recent Filing)$10.50M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Jul 31, 2025EPS Estimate
-0.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.14
Shares Outstanding72,991,390
10 Day Avg. Volume1,827,296
30 Day Avg. Volume1,775,649
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)0.82
Price to Sales (P/S)0.00
P/FCF Ratio-2.15
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue0.50
Enterprise Value/Gross Profit1.11
Enterprise Value/Ebitda-0.45
Forecast
1Y Price Target
$14.10Price Target Upside78.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
Arvinas Holding Company News
PremiumCompany Announcements
Arvinas Elects New Directors and Ratifies Auditor
PremiumCompany Announcements
Arvinas Unveils Promising ARV-393 Data at EHA Congress
PremiumCompany Announcements
Arvinas R&D President Ian Taylor Resigns
PremiumCompany Announcements
Arvinas and Pfizer Submit New Drug Application
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyVepdegestrant is positioned as a potential best-in-class treatment for ESR1m mBC patients, showing a 2.9-month PFS benefit with improved efficacy without compromising safety.
Market PositionPfizer's strong presence in breast cancer is expected to help drive the adoption of vepdegestrant.
TolerabilityVepdegestrant presents a compelling balance of efficacy and safety, potentially offering a better-tolerated option than elacestrant.
Bears Say
Market CompetitionAs a monotherapy, the drug may face competition from other treatments, potentially relegating it to a later line of therapy.
Market ConstraintsThe emergence of new data suggests a shift in treatment standards, which could limit the addressable market for Arvinas' lead drug.
Partnership UncertaintyThere is expected volatility in ARVN shares as discussions continue regarding the future of the Pfizer partnership.
Ownership Overview
2.89% Insiders
23.84% Mutual Funds
0.35% Other Institutional Investors
58.14% Public Companies and Individual Investors
ARVN FAQ
What was Arvinas Holding Company’s price range in the past 12 months?
Arvinas Holding Company lowest stock price was $5.90 and its highest was $30.24 in the past 12 months.
What is Arvinas Holding Company’s market cap?
Arvinas Holding Company’s market cap is $575.90M.
When is Arvinas Holding Company’s upcoming earnings report date?
Arvinas Holding Company’s upcoming earnings report date is Jul 31, 2025 which is in 4 days.
How were Arvinas Holding Company’s earnings last quarter?
Arvinas Holding Company released its earnings results on May 01, 2025. The company reported $1.14 earnings per share for the quarter, beating the consensus estimate of -$0.965 by $2.105.
Is Arvinas Holding Company overvalued?
According to Wall Street analysts Arvinas Holding Company’s price is currently Undervalued.
Does Arvinas Holding Company pay dividends?
Arvinas Holding Company does not currently pay dividends.
What is Arvinas Holding Company’s EPS estimate?
Arvinas Holding Company’s EPS estimate is -0.94.
How many shares outstanding does Arvinas Holding Company have?
Arvinas Holding Company has 72,991,390 shares outstanding.
What happened to Arvinas Holding Company’s price movement after its last earnings report?
Arvinas Holding Company reported an EPS of $1.14 in its last earnings report, beating expectations of -$0.965. Following the earnings report the stock price went down -24.844%.
Which hedge fund is a major shareholder of Arvinas Holding Company?
Currently, no hedge funds are holding shares in ARVN
Arvinas Holding Company Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.10 (78.71% Upside)
$14.10 (78.71% Upside)
Blogger Sentiment
Bullish
ARVN Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $62.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.2%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.76%
12-Months-Change
Fundamentals
Return on Equity
-35.41%
Trailing 12-Months
Asset Growth
-17.44%
Trailing 12-Months
Company Description
Arvinas Holding Company
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
ARVN Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive sentiment with significant progress in clinical trials, especially for Vepdegestrant and ARV-102. However, the removal of planned phase 3 trials and workforce reductions indicate challenges and strategic realignments.Read More>ARVN Stock 12 Month Forecast
Average Price Target
$14.10
▲(78.71%Upside)
Technical Analysis
Niagen Bioscience
―
Immatics
―
Opthea Limited Sponsored ADR
―
PureTech Health
―
Sionna Therapeutics, Inc.
―